BCR/ABL1 Tyrosine Seq BCR/ABL1 Tyrosine Seq

Synonyms
Allscripts (AEHR) Order Name	BCR/ABL1 Tyrosine Seq
Sunrise Clinical Manager (SCM) Order Name	BCR/ABL1 Tyrosine Seq
EPIC Order Name	BCR/ABL1, Tyrosine Kinase Inhibitor Resistance, Kinase Domain Mutation Screen, Sanger Sequencing
Clinical Info	Evaluating patients with chronic myelogenous leukemia and Philadelphia chromosome positive B-cell acute lymphoblastic leukemia receiving tyrosine kinase inhibitor (TKI) therapy, who are apparently failing treatment Preferred initial test to identify the presence of acquired BCR-ABL1 mutations associated with TKI-resistance.
Specimen Type	Blood, Bone Marrow
Container	Lavender Top Tube
Collection Instructions	Container/Tube: Lavender(EDTA) Top Tube Specimen: 10 mL Whole Blood (8 mL min) or 4 mL Bone marrow (2mL min) Transport temperature: Refrigerated Note: Refrigerated specimens must arrive within 5 days of collection, and ambient specimens must arrive within 3 days (72 hours) of collection. The following information is required: 1. Patient's fusion type (p210, p190, p205 or p230) 2. Pertinent clinical history 3. Clinical or morphologic suspicion 4. Specimen source (blood or bone marrow)
Transport Instructions
Specimen Stability	3 Days Room Temperature 5 Days Refrigerated Unacceptable Frozen
Methodology	Reverse Transcription-Polymerase Chain Reaction (RT-PCR) with Sanger Sequencing
Days Performed	TAT: 6-8 Days If BCR/ABL1 fusion type (p210, p190, p205 or p230) is not provided, BADX / BCR/ABL1, Qualitative, Diagnostic Assay, Varies will be performed at an additional charge. In the event that no fusion form (p190, p205, p210, p230) is identified by qualitative testing, this test will be canceled.
Performing Laboratory	Mayo Medical Laboratories
CPT	81170 LOINC Code: 55135-8
PDM	235768
Result Interpretation See Report Mayo test code BAKDM
Forms